M55 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Loss TrendRevenue growth and a substantial narrowing of losses indicate improving operating performance and possible cost or mix benefits. Although the company remains unprofitable, this trajectory could strengthen its ability to fund development and move toward breakeven over the next several quarters.
Asset-Light R&D StrategyThe asset sale shifts MacroGenics toward a more focused R&D model while providing substantial transaction proceeds and outsourced production support. This may reduce manufacturing responsibilities and concentrate resources on advancing antibody programs and creating future partnering or product opportunities.
Advancing Oncology PipelineProgression into Stage 2 enrollment provides stronger clinical validation than early dose escalation alone and may improve the program’s partnering potential. The absence of reported interstitial lung disease or ocular toxicity in 74 enrolled patients also supports continued development credibility.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow means MacroGenics is not yet funding its activities internally, increasing dependence on cash reserves, partnerships, asset proceeds, or future financing. Continued burn could constrain pipeline investment and weaken flexibility if profitability is delayed.
Unprofitable OperationsThe company’s core operations remain below breakeven, so revenue improvement has not yet translated into sustainable earnings. Negative operating margins leave results exposed to development spending and revenue volatility, limiting the durability of financial improvement until recurring profitability is achieved.
Eroding Shareholder EquityDeclining equity and deeply negative returns indicate that continuing losses are reducing the capital base rather than generating value for shareholders. Even with manageable leverage, this erosion can reduce financial resilience and make future funding more consequential if cash consumption persists.
MacroGenics News
M55 FAQ
What was MacroGenics’s price range in the past 12 months?
Currently, no data Available
What is MacroGenics’s market cap?
MacroGenics’s market cap is CHF174.46M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 04, 2026 which is in 19 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 13, 2026. The company reported CHF0.257 earnings per share for the quarter, beating the consensus estimate of -CHF0.065 by CHF0.321.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.26.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,700,188 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of CHF0.257 in its last earnings report, beating expectations of -CHF0.065. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in CH:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.83 (― Upside)
CHF5.83 (― Upside)
Blogger Sentiment
Neutral
CH:M55 Sentiment 75%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.40%
12-Months-Change
Fundamentals
Return on Equity
-31.27%
Trailing 12-Months
Asset Growth
40.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.